8-K filed August 10, 2023, 7:59 PM ET ticker ERNA CIK 0000748592

regulatory confidence high sentiment negative materiality 0.75

CEO resigns, then reappointed; board resignations trigger Nasdaq non-compliance

Ernexa Therapeutics Inc.

CEO Dr. Angel resigned Aug 4 citing board's exclusion from business dev; rescinded Aug 8, reappointed Aug 9.
Directors Binder and Wagner resigned Aug 8; Board reduced to two members (Wexler, Fiore).
Nasdaq notified non-compliance with independent director, audit & compensation committee rules.
Company has 45 days to submit compliance plan; up to 180-day extension possible if plan accepted.
Company actively searching for new directors to fill vacancies and regain compliance.

item 3.01 item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Richard W. Wagner

Director

ERNA · Ernexa Therapeutics Inc.

Effective: 2023-08-08
Filed: August 10, 2023, 7:59 PM ET

On August 8, 2023, Mr. Brant C. Binder and Dr. Richard W. Wagner resigned from the Board

Departed

Brant C. Binder

Director

ERNA · Ernexa Therapeutics Inc.

Effective: 2023-08-08
Filed: August 10, 2023, 7:59 PM ET

On August 8, 2023, Mr. Brant C. Binder and Dr. Richard W. Wagner resigned from the Board

Departed

Matthew Angel

President and Chief Executive Officer

ERNA · Ernexa Therapeutics Inc.

Effective: 2023-08-04
Filed: August 10, 2023, 7:59 PM ET

On August 4, 2023, Dr. Matthew Angel resigned from the Board and as the Company’s President and Chief Executive Officer

Appointed

Matthew Angel

President and Chief Executive Officer

ERNA · Ernexa Therapeutics Inc.

Effective: 2023-08-09
Filed: August 10, 2023, 7:59 PM ET

the Board reappointed Dr. Angel as the Company’s President and Chief Executive Officer

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard W. Wagner resigned as Director at Ernexa Therapeutics Inc..

Action: resigned
Role: Director

Exact text from the filing

On August 8, 2023, Mr. Brant C. Binder and Dr. Richard W. Wagner resigned from the Board

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Brant C. Binder resigned as Director at Ernexa Therapeutics Inc..

Action: resigned
Role: Director

Exact text from the filing

On August 8, 2023, Mr. Brant C. Binder and Dr. Richard W. Wagner resigned from the Board

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Matthew Angel resigned as President and Chief Executive Officer at Ernexa Therapeutics Inc..

Action: resigned
Role: President and Chief Executive Officer

Exact text from the filing

On August 4, 2023, Dr. Matthew Angel resigned from the Board and as the Company’s President and Chief Executive Officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Matthew Angel was appointed as President and Chief Executive Officer at Ernexa Therapeutics Inc..

Action: reappointed
Role: President and Chief Executive Officer

Exact text from the filing

the Board reappointed Dr. Angel as the Company’s President and Chief Executive Officer

View on SEC.gov

Ernexa Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-039073

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.